Table 1.

Summary of the Best Achievements in Clinical Medicine in Diabetes and Dyslipidemia in 2020

Study	Title	Findings
Lu et al. [7]	Time in range in relation to all-cause and cardiovascular mortality in patients with type 2 diabetes: a prospective cohort study	There was a significant inverse association of TIR with the risk of all-cause and CVD mortality, supporting the validity of TIR as a surrogate marker of long-term adverse clinical outcomes in patients with T2DM.
Cannon et al. [16]	Cardiovascular outcomes with ertugliflozin in type 2 diabetes	Among patients with T2DM and atherosclerotic CVD, ertugliflozin was non-inferior to placebo with respect to major adverse CV events, but failed to show superiority.
Packer et al. [18]	Cardiovascular and renal outcomes with empagliflozin in heart failure	The empagliflozin group showed a 25% risk reduction in the composite of CV death or hospitalization for worsening HF, and the effect was consistent in patients regardless of the presence or absence of diabetes.
Rosenstock et al. [27]	Once-weekly insulin for type 2 diabetes without previous insulin treatment	Once-weekly treatment with insulin icodec had glucose-lowering efficacy and a safety profile similar to those of once-daily insulin glargine U100 in patients with type 2 diabetes.
Thethi et al. [30]	Efficacy, safety and cardiovascular outcomes of once-daily oral semaglutide in patients with type 2 diabetes: The PIONEER programme	Oral semaglutide is efficacious and well-tolerated for glycemic control of T2DM.
Park et al. [33]	Mildly abnormal lipid levels, but not high lipid variability, are associated with increased risk of myocardial infarction and stroke in “statin-naive” young population	Modestly abnormal lipid levels (total cholesterol >223 mg/dL) were associated with a higher risk for MI in the young population.
Mortensen et al. [36]	Elevated LDL cholesterol and increased risk of myocardial infarction and atherosclerotic cardiovascular disease in individuals aged 70–100 years: a contemporary primary prevention cohort	People aged 70–100 years with elevated LDL-C had the highest absolute risk of MI and atherosclerotic CVD compared with people aged 20–69 years.
Amarenco et al. [38]	Treat stroke to target investigators. A comparison of two LDL cholesterol targets after ischemic stroke	After ischemic stroke, patients who had a target LDL-C <70 mg/dL had a lower risk of subsequent CVD.
Budoff et al. [40]	Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial	Icosapent ethyl led to a significant regression of low-attenuation plaque volume on MDCT.

TIR, time in range; CVD, cardiovascular disease; T2DM, type 2 diabetes mellitus; CV, cardiovascular; HF, heart failure; MI, myocardial infarction; LDL-C, low-density lipoprotein cholesterol; MDCT, multidetector computed tomography.